Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Inflammation
Published in: Journal of Inflammation 1/2010

Open Access 01-12-2010 | Review

Anti-inflammatory treatment strategies for ischemia/reperfusion injury in transplantation

Authors: Jens Lutz, Klaus Thürmel, Uwe Heemann

Published in: Journal of Inflammation | Issue 1/2010

Login to get access

Abstract

Inflammatory reactions in the graft have a pivotal influence on acute as well as long-term graft function. The main reasons for an inflammatory reaction of the graft tissue are rejection episodes, infections as well as ischemia/reperfusion (I/R) injury. The latter is of particular interest as it affects every solid organ during the process of transplantation. I/R injury impairs acute as well as long-term graft function and is associated with an increased number of acute rejection episodes that again affect long-term graft outcome.
I/R injury is the result of ATP depletion during prolonged hypoxia. Further tissue damage results from the reperfusion of the tissue after the ischemic insult. Adaptive cellular responses activate the innate immune system with its Toll-like receptors and the complement system as well as the adaptive immune system. This results in a profound inflammatory tissue reaction with immune cells infiltrating the tissue. The damage is mediated by various cytokines, chemokines, adhesion molecules, and compounds of the extracellular matrix. The expression of these factors is regulated by specific transcription factors with NF-κB being one of the key modulators of inflammation.
Strategies to prevent or treat I/R injury include blockade of cytokines/chemokines, adhesion molecules, NF-κB, specific MAP kinases, metalloproteinases, induction of protective genes, and modulation of the innate immune system. Furthermore, preconditioning of the donor is an area of intense research. Here pharmacological treatment as well as new additives to conventional cold storage solutions have been analyzed together with new techniques for the perfusion of grafts, or methods of normothermic storage that would avoid the problem of cold damage and graft ischemia.
However, the number of clinical trials in the field of I/R injury is limited as compared to the large body of experimental knowledge that accumulated during recent years in the field of I/R injury. Future activities in the treatment of I/R injury should focus on the translation of experimental protocols into clinical trials in order to reduce I/R injury and, thus, improve short- as well as long-term graft outcome.
Literature
1.
Gueler F, Gwinner W, Schwarz A, Haller H: Long-term effects of acute ischemia and reperfusion injury. Kidney Int. 2004, 66: 523-527. 10.1111/j.1523-1755.2004.761_11.x.PubMedCrossRef
2.
Kosieradzki M, Rowinski W: Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention. Transplant Proc. 2008, 40: 3279-3288. 10.1016/j.transproceed.2008.10.004.PubMedCrossRef
3.
Ma A, Qi S, Chen H: Antioxidant therapy for prevention of inflammation, ischemic reperfusion injuries and allograft rejection. Cardiovasc Hematol Agents Med Chem. 2008, 6: 20-43. 10.2174/187152508783329966.PubMedCrossRef
4.
Meldrum DR, Dinarello CA, Cleveland JC, Cain BS, Shames BD, Meng X, Harken AH: Hydrogen peroxide induces tumor necrosis factor alpha-mediated cardiac injury by a P38 mitogen-activated protein kinase-dependent mechanism. Surgery. 1998, 124: 291-296. discussion 297.PubMedCrossRef
5.
Martinon F, Burns K, Tschopp J: The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002, 10: 417-426. 10.1016/S1097-2765(02)00599-3.PubMedCrossRef
6.
Moynagh PN: Toll-like receptor signalling pathways as key targets for mediating the anti-inflammatory and immunosuppressive effects of glucocorticoids. J Endocrinol. 2003, 179: 139-144. 10.1677/joe.0.1790139.PubMedCrossRef
7.
Polderman KH: Mechanisms of action, physiological effects, and complications of hypothermia. Crit Care Med. 2009, 37: S186-202. 10.1097/CCM.0b013e3181aa5241.PubMedCrossRef
8.
Furuichi K, Wada T, Kaneko S, Murphy PM: Roles of chemokines in renal ischemia/reperfusion injury. Front Biosci. 2008, 13: 4021-4028. 10.2741/2990.PubMedCrossRef
9.
Barklin A: Systemic inflammation in the brain-dead organ donor. Acta Anaesthesiol Scand. 2009, 53: 425-435. 10.1111/j.1399-6576.2008.01879.x.PubMedCrossRef
10.
Catania A, Lonati C, Sordi A, Gatti S: Detrimental consequences of brain injury on peripheral cells. Brain Behav Immun. 2009, 23: 877-884. 10.1016/j.bbi.2009.04.006.PubMedCrossRef
11.
Kaminska D, Tyran B, Mazanowska O, Rabczynski J, Szyber P, Patrzalek D, Chudoba P, Polak WG, Klinger M: Cytokine gene expression in kidney allograft biopsies after donor brain death and ischemia-reperfusion injury using in situ reverse-transcription polymerase chain reaction analysis. Transplantation. 2007, 84: 1118-1124. 10.1097/01.tp.0000287190.86654.74.PubMedCrossRef
12.
Pratschke J, Wilhelm MJ, Laskowski I, Kusaka M, Beato F, Tullius SG, Neuhaus P, Hancock WW, Tilney NL: Influence of donor brain death on chronic rejection of renal transplants in rats. J Am Soc Nephrol. 2001, 12: 2474-2481.PubMed
13.
Hoeven van der JA, Molema G, Ter Horst GJ, Freund RL, Wiersema J, van Schilfgaarde R, Leuvenink HG, Ploeg RJ: Relationship between duration of brain death and hemodynamic (in)stability on progressive dysfunction and increased immunologic activation of donor kidneys. Kidney Int. 2003, 64: 1874-1882. 10.1046/j.1523-1755.2003.00272.x.PubMedCrossRef
14.
Ikeda T, Yanaga K, Kishikawa K, Kakizoe S, Shimada M, Sugimachi K: Ischemic injury in liver transplantation: difference in injury sites between warm and cold ischemia in rats. Hepatology. 1992, 16: 454-461. 10.1002/hep.1840160226.PubMedCrossRef
15.
Huet PM, Nagaoka MR, Desbiens G, Tarrab E, Brault A, Bralet MP, Bilodeau M: Sinusoidal endothelial cell and hepatocyte death following cold ischemia-warm reperfusion of the rat liver. Hepatology. 2004, 39: 1110-1119. 10.1002/hep.20157.PubMedCrossRef
16.
Loor G, Schumacker PT: Role of hypoxia-inducible factor in cell survival during myocardial ischemia-reperfusion. Cell Death Differ. 2008, 15: 686-690. 10.1038/cdd.2008.13.PubMedCrossRef
17.
El Awad B, Kreft B, Wolber EM, Hellwig-Burgel T, Metzen E, Fandrey J, Jelkmann W: Hypoxia and interleukin-1beta stimulate vascular endothelial growth factor production in human proximal tubular cells. Kidney Int. 2000, 58: 43-50. 10.1046/j.1523-1755.2000.00139.x.PubMedCrossRef
18.
Bach FH, Hancock WW, Ferran C: Protective genes expressed in endothelial cells: a regulatory response to injury. Immunol Today. 1997, 18: 483-486. 10.1016/S0167-5699(97)01129-8.PubMedCrossRef
19.
Opelz G: Impact of HLA compatibility on survival of kidney transplants from unrelated live donors. Transplantation. 1997, 64: 1473-1475. 10.1097/00007890-199711270-00017.PubMedCrossRef
20.
Opelz G, Wujciak T, Dohler B, Scherer S, Mytilineos J: HLA compatibility and organ transplant survival. Collaborative Transplant Study. Rev Immunogenet. 1999, 1: 334-342.PubMed
21.
Jaswal JS, Gandhi M, Finegan BA, Dyck JR, Clanachan AS: Inhibition of p38 MAPK and AMPK restores adenosine-induced cardioprotection in hearts stressed by antecedent ischemia by altering glucose utilization. Am J Physiol Heart Circ Physiol. 2007, 293: H1107-1114. 10.1152/ajpheart.00455.2007.PubMedCrossRef
22.
Lutz J, Yao Y, Song E, Antus B, Hamar P, Liu S, Heemann U: Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation. 2005, 79: 655-661. 10.1097/01.TP.0000151644.85832.B5.PubMedCrossRef
23.
Furuichi K, Wada T, Iwata Y, Kitagawa K, Kobayashi K, Hashimoto H, Ishiwata Y, Tomosugi N, Mukaida N, Matsushima K, et al: Gene therapy expressing amino-terminal truncated monocyte chemoattractant protein-1 prevents renal ischemia-reperfusion injury. J Am Soc Nephrol. 2003, 14: 1066-1071. 10.1097/01.ASN.0000059339.14780.E4.PubMedCrossRef
24.
Wanderer AA: Ischemic-reperfusion syndromes: biochemical and immunologic rationale for IL-1 targeted therapy. Clin Immunol. 2008, 128: 127-132. 10.1016/j.clim.2008.03.514.PubMedCrossRef
25.
Bresnihan B, Cunnane G: Interleukin-1 receptor antagonist. Rheum Dis Clin North Am. 1998, 24: 615-628. 10.1016/S0889-857X(05)70029-6.PubMedCrossRef
26.
Rusai K, Huang H, Sayed N, Strobl M, Roos M, Schmaderer C, Heemann U, Lutz J: Administration of interleukin-1 receptor antagonist ameliorates renal ischemia-reperfusion injury. Transpl Int. 2008, 21: 572-580. 10.1111/j.1432-2277.2008.00651.x.PubMedCrossRef
27.
Zhou T, Sun GZ, Zhang MJ, Chen JL, Zhang DQ, Hu QS, Chen YY, Chen N: Role of adhesion molecules and dendritic cells in rat hepatic/renal ischemia-reperfusion injury and anti-adhesive intervention with anti-P-selectin lectin-EGF domain monoclonal antibody. World J Gastroenterol. 2005, 11: 1005-1010.PubMedPubMedCentralCrossRef
28.
Martinez-Mier G, Toledo-Pereyra LH, Ward PA: Adhesion molecules in liver ischemia and reperfusion. J Surg Res. 2000, 94: 185-194. 10.1006/jsre.2000.6006.PubMedCrossRef
29.
Wang X, Feuerstein GZ: Induced expression of adhesion molecules following focal brain ischemia. J Neurotrauma. 1995, 12: 825-832. 10.1089/neu.1995.12.825.PubMedCrossRef
30.
Kupiec-Weglinski JW, Busuttil RW: Ischemia and reperfusion injury in liver transplantation. Transplant Proc. 2005, 37: 1653-1656. 10.1016/j.transproceed.2005.03.134.PubMedCrossRef
31.
Vincenti F, Mendez R, Pescovitz M, Rajagopalan PR, Wilkinson AH, Butt K, Laskow D, Slakey DP, Lorber MI, Garg JP, Garovoy M: A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant. 2007, 7: 1770-1777. 10.1111/j.1600-6143.2007.01845.x.PubMedCrossRef
32.
Kahan BD, Stepkowski S, Kilic M, Katz SM, Van Buren CT, Welsh MS, Tami JA, Shanahan WR: Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection. Transplantation. 2004, 78: 858-863. 10.1097/01.TP.0000128857.77893.D2.PubMedCrossRef
33.
Latanich CA, Toledo-Pereyra LH: Searching for NF-kappaB-based treatments of ischemia reperfusion injury. J Invest Surg. 2009, 22: 301-315. 10.1080/08941930903040155.PubMedCrossRef
34.
Onai Y, Suzuki J, Kakuta T, Maejima Y, Haraguchi G, Fukasawa H, Muto S, Itai A, Isobe M: Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc Res. 2004, 63: 51-59. 10.1016/j.cardiores.2004.03.002.PubMedCrossRef
35.
Itoh M, Takaoka M, Shibata A, Ohkita M, Matsumura Y: Preventive effect of lactacystin, a selective proteasome inhibitor, on ischemic acute renal failure in rats. J Pharmacol Exp Ther. 2001, 298: 501-507.PubMed
36.
Yao JH, Li YH, Wang ZZ, Zhang XS, Wang YZ, Yuan JC, Zhou Q, Liu KX, Tian XF: Proteasome inhibitor lactacystin ablates liver injury induced by intestinal ischaemia-reperfusion. Clin Exp Pharmacol Physiol. 2007, 34: 1102-1108.PubMed
37.
Phillips JB, Williams AJ, Adams J, Elliott PJ, Tortella FC: Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke. 2000, 31: 1686-1693.PubMedCrossRef
38.
Shigeoka AA, Holscher TD, King AJ, Hall FW, Kiosses WB, Tobias PS, Mackman N, McKay DB: TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and -independent pathways. J Immunol. 2007, 178: 6252-6258.PubMedCrossRef
39.
Pulskens WP, Teske GJ, Butter LM, Roelofs JJ, Poll van der T, Florquin S, Leemans JC: Toll-like receptor-4 coordinates the innate immune response of the kidney to renal ischemia/reperfusion injury. PLoS One. 2008, 3: e3596-10.1371/journal.pone.0003596.PubMedPubMedCentralCrossRef
40.
Kruger B, Krick S, Dhillon N, Lerner SM, Ames S, Bromberg JS, Lin M, Walsh L, Vella J, Fischereder M, et al: Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci USA. 2009, 106: 3390-3395. 10.1073/pnas.0810169106.PubMedPubMedCentralCrossRef
41.
Rusai DS K, Baumann M, Wagner B, Strobl M, Schmaderer C, Roos M, Kirschning C, Heemann U, Lutz J: Toll-like Receptor 2 and 4 in Renal Ischemia/Reperfusion Injury. J Ped Nephrol. 2009, 25 (5): 853-60. 10.1007/s00467-009-1422-4.CrossRef
42.
Li C, Ha T, Kelley J, Gao X, Qiu Y, Kao RL, Browder W, Williams DL: Modulating Toll-like receptor mediated signaling by (1-->3)-beta-D-glucan rapidly induces cardioprotection. Cardiovasc Res. 2004, 61: 538-547. 10.1016/j.cardiores.2003.09.007.PubMedCrossRef
43.
Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, Fleisig AJ, Agnew ML, Hampton CR, Rothnie CL, Spring DJ, et al: Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation. 2006, 114: I270-274. 10.1161/CIRCULATIONAHA.105.000901.PubMedCrossRef
44.
Hepburn NJ, Ruseva MM, Harris CL, Morgan BP: Complement, roles in renal disease and modulation for therapy. Clin Nephrol. 2008, 70: 357-376.PubMedCrossRef
45.
Jang HR, Ko GJ, Wasowska BA, Rabb H: The interaction between ischemia-reperfusion and immune responses in the kidney. J Mol Med. 2009, 87: 859-864. 10.1007/s00109-009-0491-y.PubMedCrossRef
46.
Diepenhorst GM, van Gulik TM, Hack CE: Complement-mediated ischemia-reperfusion injury: lessons learned from animal and clinical studies. Ann Surg. 2009, 249: 889-899. 10.1097/SLA.0b013e3181a38f45.PubMedCrossRef
47.
Zheng X, Feng B, Chen G, Zhang X, Li M, Sun H, Liu W, Vladau C, Liu R, Jevnikar AM, et al: Preventing renal ischemia-reperfusion injury using small interfering RNA by targeting complement 3 gene. Am J Transplant. 2006, 6: 2099-2108. 10.1111/j.1600-6143.2006.01427.x.PubMedCrossRef
48.
Zheng X, Zhang X, Feng B, Sun H, Suzuki M, Ichim T, Kubo N, Wong A, Min LR, Budohn ME, et al: Gene silencing of complement C5a receptor using siRNA for preventing ischemia/reperfusion injury. Am J Pathol. 2008, 173: 973-980. 10.2353/ajpath.2008.080103.PubMedPubMedCentralCrossRef
49.
Ferraresso M, Macor P, Valente M, Della Barbera M, D'Amelio F, Borghi O, Raschi E, Durigutto P, Meroni P, Tedesco F: Posttransplant ischemia-reperfusion injury in transplanted heart is prevented by a minibody to the fifth component of complement. Transplantation. 2008, 86: 1445-1451. 10.1097/TP.0b013e31818a68e2.PubMedCrossRef
50.
Wang DS, Li Y, Dou KF, Li KZ, Song ZS: Utility of adenovirus-mediated Fas ligand and bcl-2 gene transfer to modulate rat liver allograft survival. Hepatobiliary Pancreat Dis Int. 2006, 5: 505-510.PubMed
51.
Rentsch M, Kienle K, Mueller T, Vogel M, Jauch KW, Pullmann K, Obed A, Schlitt HJ, Beham A: Adenoviral bcl-2 transfer improves survival and early graft function after ischemia and reperfusion in rat liver transplantation. Transplantation. 2005, 80: 1461-1467. 10.1097/01.tp.0000178293.65311.8b.PubMedCrossRef
52.
Huang J, Nakamura K, Ito Y, Uzuka T, Morikawa M, Hirai S, Tomihara K, Tanaka T, Masuta Y, Ishii K, et al: Bcl-xL gene transfer inhibits Bax translocation and prolongs cardiac cold preservation time in rats. Circulation. 2005, 112: 76-83. 10.1161/CIRCULATIONAHA.105.535740.PubMedCrossRef
53.
Cooke DT, Hoyt EG, Robbins RC: Overexpression of human Bcl-2 in syngeneic rat donor lungs preserves posttransplant function and reduces intragraft caspase activity and interleukin-1beta production. Transplantation. 2005, 79: 762-767. 10.1097/01.TP.0000153368.08861.15.PubMedCrossRef
54.
Braudeau C, Bouchet D, Tesson L, Iyer S, Remy S, Buelow R, Anegon I, Chauveau C: Induction of long-term cardiac allograft survival by heme oxygenase-1 gene transfer. Gene Ther. 2004, 11: 701-710. 10.1038/sj.gt.3302208.PubMedCrossRef
55.
Blydt-Hansen TD, Katori M, Lassman C, Ke B, Coito AJ, Iyer S, Buelow R, Ettenger R, Busuttil RW, Kupiec-Weglinski JW: Gene transfer-induced local heme oxygenase-1 overexpression protects rat kidney transplants from ischemia/reperfusion injury. J Am Soc Nephrol. 2003, 14: 745-754. 10.1097/01.ASN.0000050760.87113.25.PubMedCrossRef
56.
Chauveau C, Bouchet D, Roussel JC, Mathieu P, Braudeau C, Renaudin K, Tesson L, Soulillou JP, Iyer S, Buelow R, Anegon I: Gene transfer of heme oxygenase-1 and carbon monoxide delivery inhibit chronic rejection. Am J Transplant. 2002, 2: 581-592. 10.1034/j.1600-6143.2002.20702.x.PubMedCrossRef
57.
Ke B, Buelow R, Shen XD, Melinek J, Amersi F, Gao F, Ritter T, Volk HD, Busuttil RW, Kupiec-Weglinski JW: Heme oxygenase 1 gene transfer prevents CD95/Fas ligand-mediated apoptosis and improves liver allograft survival via carbon monoxide signaling pathway. Hum Gene Ther. 2002, 13: 1189-1199. 10.1089/104303402320138970.PubMedCrossRef
58.
Daemen MA, van 't Veer C, Denecker G, Heemskerk VH, Wolfs TG, Clauss M, Vandenabeele P, Buurman WA: Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest. 1999, 104: 541-549. 10.1172/JCI6974.PubMedPubMedCentralCrossRef
59.
Fuller TF, Freise CE, Serkova N, Niemann CU, Olson JL, Feng S: Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury. Transplantation. 2003, 76: 1594-1599. 10.1097/01.TP.0000095897.38634.30.PubMedCrossRef
60.
Lieberthal W, Fuhro R, Andry CC, Rennke H, Abernathy VE, Koh JS, Valeri R, Levine JS: Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol. 2001, 281: F693-706.PubMed
61.
62.
Evans PC, Ovaa H, Hamon M, Kilshaw PJ, Hamm S, Bauer S, Ploegh HL, Smith TS: Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J. 2004, 378: 727-734. 10.1042/BJ20031377.PubMedPubMedCentralCrossRef
63.
Evans PC, Smith TS, Lai MJ, Williams MG, Burke DF, Heyninck K, Kreike MM, Beyaert R, Blundell TL, Kilshaw PJ: A novel type of deubiquitinating enzyme. J Biol Chem. 2003, 278: 23180-23186. 10.1074/jbc.M301863200.PubMedCrossRef
64.
Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, Hurley P, Chien M, Chai S, Hitotsumatsu O, et al: The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol. 2004, 5: 1052-1060. 10.1038/ni1110.PubMedCrossRef
65.
Lutz J, Luong le A, Strobl M, Deng M, Huang H, Anton M, Zakkar M, Enesa K, Chaudhury H, Haskard DO, et al: The A20 gene protects kidneys from ischaemia/reperfusion injury by suppressing pro-inflammatory activation. J Mol Med. 2008, 86: 1329-1339. 10.1007/s00109-008-0405-4.PubMedCrossRef
66.
Xu MQ, Yan LN, Gou XH, Li DH, Huang YC, Hu HY, Wang LY, Han L: Zinc finger protein A20 promotes regeneration of small-for-size liver allograft and suppresses rejection and results in a longer survival in recipient rats. J Surg Res. 2009, 152: 35-45. 10.1016/j.jss.2008.04.029.PubMedCrossRef
67.
Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N, Vallon V: (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiol Rev. 2006, 86: 1151-1178. 10.1152/physrev.00050.2005.PubMedCrossRef
68.
Bell LM, Leong ML, Kim B, Wang E, Park J, Hemmings BA, Firestone GL: Hyperosmotic stress stimulates promoter activity and regulates cellular utilization of the serum- and glucocorticoid-inducible protein kinase (Sgk) by a p38 MAPK-dependent pathway. J Biol Chem. 2000, 275: 25262-25272. 10.1074/jbc.M002076200.PubMedCrossRef
69.
Firestone GL, Giampaolo JR, O'Keeffe BA: Stimulus-dependent regulation of serum and glucocorticoid inducible protein kinase (SGK) transcription, subcellular localization and enzymatic activity. Cell Physiol Biochem. 2003, 13: 1-12. 10.1159/000070244.PubMedCrossRef
70.
Leong ML, Maiyar AC, Kim B, O'Keeffe BA, Firestone GL: Expression of the serum- and glucocorticoid-inducible protein kinase, Sgk, is a cell survival response to multiple types of environmental stress stimuli in mammary epithelial cells. J Biol Chem. 2003, 278: 5871-5882. 10.1074/jbc.M211649200.PubMedCrossRef
71.
Cursio R, Mari B, Louis K, Rostagno P, Saint-Paul MC, Giudicelli J, Bottero V, Anglard P, Yiotakis A, Dive V, et al: Rat liver injury after normothermic ischemia is prevented by a phosphinic matrix metalloproteinase inhibitor. FASEB J. 2002, 16: 93-95.PubMed
72.
Montaner J, Alvarez-Sabin J, Molina C, Angles A, Abilleira S, Arenillas J, Gonzalez MA, Monasterio J: Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke. 2001, 32: 1759-1766. 10.1161/hs1201.99512.PubMedCrossRef
73.
Shirahane K, Yamaguchi K, Koga K, Watanabe M, Kuroki S, Tanaka M: Hepatic ischemia/reperfusion injury is prevented by a novel matrix metalloproteinase inhibitor, ONO-4817. Surgery. 2006, 139: 653-664. 10.1016/j.surg.2005.10.002.PubMedCrossRef
74.
Jamieson RW, Friend PJ: Organ reperfusion and preservation. Front Biosci. 2008, 13: 221-235. 10.2741/2672.PubMedCrossRef
75.
Koike N, Takeyoshi I, Ohki S, Tokumine M, Matsumoto K, Morishita Y: Effects of adding P38 mitogen-activated protein-kinase inhibitor to celsior solution in canine heart transplantation from non-heart-beating donors. Transplantation. 2004, 77: 286-292. 10.1097/01.TP.0000101039.12835.A4.PubMedCrossRef
76.
Yoshinari D, Takeyoshi I, Kobayashi M, Koyama T, Iijima K, Ohwada S, Matsumoto K, Morishita Y: Effects of a p38 mitogen-activated protein kinase inhibitor as an additive to university of wisconsin solution on reperfusion injury in liver transplantation. Transplantation. 2001, 72: 22-27. 10.1097/00007890-200107150-00007.PubMedCrossRef
77.
Hauet T, Goujon JM, Baumert H, Petit I, Carretier M, Eugene M, Vandewalle A: Polyethylene glycol reduces the inflammatory injury due to cold ischemia/reperfusion in autotransplanted pig kidneys. Kidney Int. 2002, 62: 654-667. 10.1046/j.1523-1755.2002.00473.x.PubMedCrossRef
78.
Schnuelle P, Gottmann U, Hoeger S, Boesebeck D, Lauchart W, Weiss C, Fischereder M, Jauch KW, Heemann U, Zeier M, et al: Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA. 2009, 302: 1067-1075. 10.1001/jama.2009.1310.PubMedCrossRef
79.
Moers C, Smits JM, Maathuis MH, Treckmann J, van Gelder F, Napieralski BP, van Kasterop-Kutz M, Heide van der JJ, Squifflet JP, van Heurn E, et al: Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med. 2009, 360: 7-19. 10.1056/NEJMoa0802289.PubMedCrossRef
80.
Maathuis MH, Manekeller S, Plaats van der A, Leuvenink HG, t Hart NA, Lier AB, Rakhorst G, Ploeg RJ, Minor T: Improved kidney graft function after preservation using a novel hypothermic machine perfusion device. Ann Surg. 2007, 246: 982-988. 10.1097/SLA.0b013e31815c4019. discussion 989-991.PubMedCrossRef
81.
Wight J, Chilcott J, Holmes M, Brewer N: The clinical and cost-effectiveness of pulsatile machine perfusion versus cold storage of kidneys for transplantation retrieved from heart-beating and non-heart-beating donors. Health Technol Assess. 2003, 7: 1-94.PubMedCrossRef
82.
Stubenitsky BM, Booster MH, Brasile L, Araneda D, Haisch CE, Kootstra G: Exsanguinous metabolic support perfusion--a new strategy to improve graft function after kidney transplantation. Transplantation. 2000, 70: 1254-1258. 10.1097/00007890-200010270-00024.PubMedCrossRef
83.
Metcalfe MS, Waller JR, Hosgood SA, Shaw M, Hassanein W, Nicholson ML: A paired study comparing the efficacy of renal preservation by normothermic autologous blood perfusion and hypothermic pulsatile perfusion. Transplant Proc. 2002, 34: 1473-1474. 10.1016/S0041-1345(02)02935-4.PubMedCrossRef
84.
Valero R, Garcia-Valdecasas JC, Tabet J, Taura P, Rull R, Beltran J, Garcia F, Gonzalez FX, Lopez-Boado MA, Cabrer C, Visa J: Hepatic blood flow and oxygen extraction ratio during normothermic recirculation and total body cooling as viability predictors in non-heart-beating donor pigs. Transplantation. 1998, 66: 170-176. 10.1097/00007890-199807270-00005.PubMedCrossRef
Metadata
Title
Anti-inflammatory treatment strategies for ischemia/reperfusion injury in transplantation
Authors
Jens Lutz
Klaus Thürmel
Uwe Heemann
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue 1/2010
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/1476-9255-7-27

Other articles of this Issue 1/2010

Journal of Inflammation 1/2010 Go to the issue

Research

Signaling pathways involved in LPS induced TNFalpha production in human adipocytes

Research

Pharmacokinetics of Linezolid and Ertapenem in experimental parapneumonic pleural effusion

Review

Protein targets of inflammatory serine proteases and cardiovascular disease

Research

Increased levels of circulating Annexin A5 in Familial Mediterranean fever

Research

Proposed protective mechanism of the pancreas in the rat

Research

Early lactate clearance is associated with biomarkers of inflammation, coagulation, apoptosis, organ dysfunction and mortality in severe sepsis and septic shock
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits